Plain-English translation of NCT04570943 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment plan for locally advanced pancreatic cancer—cancer that has grown significantly but has not spread to distant parts of the body. The plan combines two chemotherapy drugs given in sequence: first Gembrax (gemcitabine and nab-paclitaxel), then FOLFIRINOX (a combination of four drugs). After the chemotherapy, patients receive a type of radiation therapy called stereotactic MRI-guided adaptive radiotherapy, which uses advanced imaging to target the tumor very precisely while sparing surrounding healthy tissue.
Pancreatic cancer is one of the most serious cancers, with very poor survival rates, and about 30% of patients have cancer that cannot be surgically removed when diagnosed. Current treatments don't work well enough for these patients. This trial is testing whether combining multiple chemotherapy drugs with advanced radiation can shrink the tumor, control the cancer in the local area, and potentially help patients live longer.
You likely qualify if…
You likely don't qualify if…
You would start by receiving the first chemotherapy drug combination (Gembrax) given on specific days with rest periods in between. After completing that phase, you would then receive the second chemotherapy combination (FOLFIRINOX). Following chemotherapy, you would undergo a specialized form of radiation therapy guided by MRI imaging, which allows doctors to target your tumor very precisely. Throughout the trial, you would have regular blood tests and imaging scans to monitor how the cancer is responding and how you are tolerating the treatment. The entire treatment process typically takes several months, and you would be closely monitored by the medical team for side effects and how well the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France